WO/2014/094844 LOCALIZED DISINFECTION SYSTEM FOR LARGE WATER BODIES||WO||26.06.2014|
||PCT/EP2012/076170||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN, Fernando Benjamin|
The present disclosure relates to a method for controlling the microbiological properties of a portion of water within a large body of water by treating such zone with chemical agents, according to the temperature of the water, its salinity, its dilution power and the diffusion of chemicals within the large water body.
WO/2013/180596 "DOLG M3" TACTICAL GUN BELT||WO||05.12.2013|
||PCT/RU2013/000102||KHARLAMPOV, Vladimir Vladimirovich||KHARLAMPOV, Vladimir Vladimirovich|
The invention relates to gun technology and, specifically, to belts for a gun used by special detachments. The tactical gun belt comprises a length-adjustable sling in the form of a loop, a carrying-sling clamp on the barrel, a rapidly detachable element for fixing to the gun barrel block and an element for fixing to the gun butt, or an element for fixing to the rear carrying-sling clamp on the gun breech, a sling-adjustment unit, and a tightening strap which passes through the sling-adjustment unit, wherein one end of said sling is fixed via the rapidly detachable element to the carrying-sling clamp on the barrel, and the other end is left free. The novelty resides in the fact that the belt additionally comprises a rapid-adjustment unit through which the sling in the form of a loop passes. Such an embodiment of a gun belt makes it possible very rapidly to adjust the length of the belt and to incorporate a large adjustment margin of the basic loop, which makes it possible to transform and use the belt on virtually any type of personal small arms: on submachine guns, automatic rifles, sniper rifles, smooth-bore guns, etc.
WO/2013/174847 LOW -MOLECULAR -WEIGHT BIOTECHNOLOGICAL CHONDROITIN 6 - SULPHATE FOR PREVENTION OF OSTEOARTHRITIS||WO||28.11.2013|
||PCT/EP2013/060471||GNOSIS S.P.A.||MIRAGLIA, Niccolò|
Disclosed is a low-molecular-weight (1000-5000 daltons) chondroitin sulphate (CS) produced by chemical sulphation and subsequent depolymerisation of a non-sulphated chondroitin backbone obtained with biotechnology techniques. The CS described is substantially monosulphated, mainly at the 6-position, with very little sulphation at the 4-position, and with a mono/disulphated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin 6-sulphate (C6S) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes.
WO/2013/160129 METHOD AND SYSTEM FOR THE ADMINISTRATION OF A PULMONARY SURFACTANT BY ATOMIZATION||WO||31.10.2013|
||PCT/EP2013/057744||CHIESI FARMACEUTICI S.P.A.||DELLACA', Raffaele|
The method and system according to preferred embodiments of the present invention allows optimizing the dispensing of aerosol medicaments. In particular the system according to a preferred embodiment of the present invention allows the administration of an exogenous pulmonary surfactant to very young patients (e.g. preterm neonates). A catheter (101) conveys atomized surfactant directly to the retro-pharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonates suffering from neonatal Respiratory Distress Syndrome (nRDS). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. In a preferred embodiment of the present invention the delivery of the atomized medicament is done by means of an air blasting technique.
WO/2013/163633 ANTI-GCC ANTIBODY MOLECULES AND USE OF SAME TO TEST FOR SUSCEPTIBILITY TO GCC-TARGETED THERAPY||WO||31.10.2013|
||PCT/US2013/038542||MILLENNIUM PHARMACEUTICALS, INC.||FRANK, Helen, Alison|
Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides diagnostic methods for identifying patients who should receive a GCC-targeted therapy utilizing the anti-GCC antibodies provided herein. The anti-GCC antibody molecules are useful as naked antibody molecules and as components of immunoconjugates. Accordingly, in another aspect, the invention features immunoconjugates comprising an anti-GCC antibody molecule described herein and a therapeutic agent or label. The invention also features methods of using the anti-GCC antibody molecules and immunoconjucates described herein, e.g., for detection of GCC and of cells or tissues that express GCC. Such methods are useful, inter alia, for diagnosis, prognosis, imaging, or staging of a GCC-mediated disease. Accordingly, in some aspects, the invention features methods of identifying a subject for treatment with a GCC- targeted therapy, e.g., an anti-GCC antibody therapy, e.g., an immunoconjugate comprising an anti-GCC antibody conjugated with a therapeutic agent.
WO/2013/156488 OPTIMISED SUBCUTANEOUS THERAPEUTIC AGENTS||WO||24.10.2013|
||PCT/EP2013/057928||CANTAB BIOPHARMACEUTICALS PATENTS LIMITED||HENRY, William|
Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.
WO/2013/158874 METHODS OF PRODUCING ANAMORELIN HYDROCHLORIDE HAVING CONTROLLED CHLORIDE CONTENT||WO||24.10.2013|
||PCT/US2013/037159||HELSINN HEALTHCARE SA||KUWABE, Shin-itsu|
The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
WO/2013/149350 TWIN SCREW EXTRUDER PRESS FOR SOLID/FLUID SEPARATION||WO||10.10.2013|
||PCT/CA2013/050279||GREENFIELD SPECIALTY ALCOHOLS INC.||LEHOUX, Richard, Romeo|
Disclosed is a solid/liquid separation apparatus including an extruder press combined with a solid/fluid separation module for separating fluid from a mass of solids compressed by the extruder at elevated pressures. The extruder includes two or more extruder screws with flighting intercalated at least along a part of the extruder barrel. The separation module forms a continuation of the barrel, receives the pressurized mass and at least a portion of the twin screws, and includes a filter pack consisting of a filter plate and a backer plate. The filter plate has a throughgoing filter slot extending away from a core opening and into the filter plate for directing fluid away from the core opening. The backer plate has a core opening shaped and sized equal to the barrel and defines a passage for guiding fluid collected in the filter slot to an exterior of the filter pack.
WO/2013/142377 MODIFIED MAREK'S DISEASE VIRUS, AND VACCINES MADE THEREFROM||WO||26.09.2013|
||PCT/US2013/032539||MERIAL LIMITED||PRITCHARD, Joyce|
The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent.
WO/2013/127729 6 - ALKYNYL PYRIDINES AS SMAC MIMETICS||WO||06.09.2013|
||PCT/EP2013/053689||BOEHRINGER INGELHEIM INTERNATIONAL GMBH||REISER, Ulrich|
This invention relates to 6-alkynyl-pyridines of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R5 have the meanings given in the claims and in the specification.